- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 1: Formulary Exclusivity Deals
The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.
The panelists discuss the evidence that is weighed when determining whether or not to include a particular therapy on their regimens.
Cost is a significant factor, admitted Matthew D. Harman, PharmD, MPH, especially since many payers felt burned by the price of Sovaldi the first time around. However, Ed Cohen, PharmD, FAPhA, said Walgreens stays neutral for of its payer clients and adheres to their formulary practices.
Steven Miller, MD, MBA, explained that since Harvoni and Viekira Pak seem to be equivalent in both use and outcome based on the studies, Express Scripts’ independent committee labelled both drugs as optional and let plans choose which one they wanted to add.
“Our national preferred formulary chose Viekira Pak, many of our other clients have chosen Harvoni,” he said. “We are fine with both and we have negotiated really great rates for all of our clients regardless of the products they’ve chosen.”
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More
Frameworks for Advancing Health Equity: Health Equity by Design
July 23rd 2024Melissa Clarke, MD, CMQ, the chief health equity officer at Elevance Health, explains "Health Equity by Design" and how Elevance Health is committed to ensuring a personalized and intentional approach for all its members.
Listen
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
